β-内酰胺类与非β-内酰胺类抗生素与结肠切除术手术部位感染
该回顾性队列研究基于密歇根外科质量协作组2013年1月至2018年2月数据,比较结肠切除术患者预防性静脉使用推荐β-内酰胺类与非β-内酰胺类抗生素后的手术部位感染率。9,949例中9,411例(94.6%)用β-内酰胺类、538例(5.4%)用非β-内酰胺类,总体SSI 622例(6.3%)。混合效应回归显示非β-内酰胺方案与更高的SSI odds相关(OR 1.65;95%CI 1.20–2.26;p<0.01)。
要点
- 结肠切除术预防性使用β-内酰胺类抗生素者SSI风险低于非β-内酰胺类。
- 即使符合国家推荐,非β-内酰胺方案仍与更高SSI odds相关(OR 1.65)。
- 应尽可能处方β-内酰胺类预防,仅在真正过敏或有临床指征时选用替代方案。
核心结论
- 结肠切除术患者接受β-内酰胺类抗生素预防者发生SSI的可能性低于接受非β-内酰胺类者,即使所用抗生素符合国家推荐。
研究设计与样本
- 回顾性队列研究,数据来自密歇根外科质量协作组2013年1月至2018年2月采集的结肠切除术患者(25个CPT编码)。
- 共纳入9,949例患者,比较预防性静脉使用推荐β-内酰胺类与非β-内酰胺类抗生素后的SSI率。
- SSI按二分类变量(无SSI vs SSI)比较,采用混合效应回归分析抗生素类型与SSI的关联。
主要发现
- 9,411例(94.6%)接受β-内酰胺类,538例(5.4%)接受非β-内酰胺类。
- 总体622例(6.3%)发生SSI;β-内酰胺组571例(6.1%),非β-内酰胺组51例(9.5%)。
- 混合效应logistic回归显示,非β-内酰胺预防方案与显著更高的SSI odds相关(OR 1.65;95%CI 1.20–2.26;p<0.01)。
临床怎么用
- 结肠切除术围术期预防性抗生素应尽可能选择β-内酰胺类。
- 非β-内酰胺类替代方案应保留给真正过敏或有临床指征的少数患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical site infections (SSIs) represent a significant preventable source of morbidity, mortality, and cost. Prophylactic antibiotics have been shown to decrease SSI rates, and β-lactam antibiotics are recommended by national guidelines. It is currently unclear whether recommended β-lactam and recommended non-β-lactam antibiotic regimens are equivalent with respect to SSI risk reduction in colectomy patients. STUDY DESIGN: We conducted a retrospective cohort study of SSI rates between prophylactic intravenously administered recommended β-lactam and non-β-lactam in colectomy patients (25 CPT codes) collected by the Michigan Surgical Quality Collaborative from January 2013 to February 2018. Surgical site infection rates were compared as a dichotomous variable (no SSI vs SSI). Mixed-effects regression was used to compare the association between receiving a β-lactam or non-β-lactam antibiotic and likelihood of having an SSI. RESULTS: Of 9,949 patients, 9,411 (94.6%) received β-lactam antibiotics and 538 (5.4%) received non-β-lactam antibiotics. Overall, there were 622 (6.3%) patients with SSIs. Of the patients receiving β-lactam antibiotics, SSIs developed in 571 (6.1%) compared with 51 (9.5%) patients in the non-β-lactam group. After applying mixed-effects logistic regression, prophylactic treatment with a non-β-lactam regimen was associated with significantly higher odds of surgical site infection (odds ratio 1.65; 95% CI 1.20 to 2.26; p < 0.01). CONCLUSIONS: Colectomy patients receiving β-lactam antibiotics had a lower likelihood of SSI compared with those receiving non-β-lactam antibiotics, even when antibiotics were compliant with national recommendations. Our findings suggest that surgeons should prescribe β-lactam antibiotics for prophylaxis whenever possible, reserving alternatives for those rare patients with true allergies or clinical indications for non-β-lactam antibiotic prophylaxis.
引用
- Kuriakose JP, Vu J, Karmakar M, et al. β-Lactam vs Non-β-Lactam Antibiotics and Surgical Site Infection in Colectomy Patients. J Am Coll Surg. 2019. PMID: 31377412. doi:10.1016/j.jamcollsurg.2019.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。